Imlygic (talimogene laherparepvec) / Amgen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imlygic (talimogene laherparepvec) / Amgen
MASTERKEY 232, NCT02626000 / 2015-003011-38: Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

Completed
1b
36
Europe, Canada, US, RoW
Talimogene Laherparepvec, IMLYGIC®, Pembrolizumab, KEYTRUDA®
Amgen, Merck Sharp & Dohme LLC
Carcinoma of the Head and Neck
11/17
08/20
NCT03088176: Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Active, not recruiting
1b
4
US
Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Imlygic, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib, Tafinlar, Trametinib, Mekinist
West Cancer Center, University of Tennessee Health Science Center, Amgen
Melanoma, BRAF Gene Mutation
11/20
06/21
KEYNOTE-034, NCT02263508 / 2014-000185-22: Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark Advanced melanoma
Mar 2016 - Mar 2016: Advanced melanoma
Checkmark ECC 2015
More
Terminated
1b
713
Europe, Canada, US, RoW
Talimogene Laherparepvec, IMLYGIC®, OncoVEX^GM-CSF, T-VEC, Pembrolizumab, MK-3475, Keytruda®, Placebo
Amgen, Merck Sharp & Dohme LLC
Melanoma
03/21
03/21
NCT03554044: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Active, not recruiting
1b
20
US
Anastrozole, Arimidex, ICI-D1033, ZD-1033, Exemestane, Aromasin, FCE-24304, Fulvestrant, Faslodex, ICI 182,780, ZD9238, Letrozole, CGS 20267, Femara, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC, OncoVEXGM-CSF, Tamoxifen, Nolvadex, Nab paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin
University of California, San Francisco, Amgen
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
04/25
04/25
NCT00402025: Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

Completed
1
17
US
Talimogene Laherparepvec, OncoVEX^GM-CSF, T-VEC, IMLYGIC
BioVex Limited
Pancreatic Cancer
01/08
01/08
NCI-2018-00109, NCT03430687: Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

Withdrawn
1
0
US
Laboratory Biomarker Analysis, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
University of California, San Francisco, Amgen
Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
12/19
12/20
NCT02890368: Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Checkmark For advanced relapsed/refractory hematologic malignancies
Jan 2020 - Jan 2020: For advanced relapsed/refractory hematologic malignancies
Hourglass Oct 2019 - Dec 2019 : For CTCL patients on continuation therapy
Checkmark Updated data for CTCL at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: Updated data for CTCL at ASH 2018 [screenshot]
More
Terminated
1
56
US
TTI-621 Monotherapy, SIRPα-IgG1 Fc, TTI-621 + PD-1/PD-L1 Inhibitor, SIRPα-IgG1 Fc + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a, SIRPα-IgG1 Fc + pegylated interferon-α2a, TTI-621 + T-Vec, SIRPα-IgG1 Fc + talimogene laherparepvec, TTI-621 + radiation, SIRPα-IgG1 Fc + radiation
Pfizer
Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma
03/20
03/20
NCT03256344: Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Completed
1
36
Europe, US, RoW
Talimogene Laherparepvec, IMLYGIC, Atezolizumab, MPDL3280A
Amgen, Roche-Genentech
Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
05/20
12/21
NCT03064763: Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Completed
1
18
Japan
Talimogene laherparepvec, Imlygic, T-VEC
Amgen
Unresectable Stage IIIB-IV Malignant Melanoma
08/20
01/23
NCT02756845 / 2015-003645-25: Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Completed
1
15
Europe, Canada, US
Talimogene Laherparepvec, TVEC
Amgen
Advanced Non CNS Tumors
01/22
11/22
PROMETEO, NCT03802604: Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

Active, not recruiting
1
28
Europe
Talimogene laherparepvec, T-VEC, Imlygic, Atezolizumab, Tecentric
SOLTI Breast Cancer Research Group, Amgen, Roche Pharma AG
Breast Cancer
04/22
04/25
NCT03086642: Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Active, not recruiting
1
9
US
Talimogene laherparepvec, T-Vec, T Vec
Karie D. Runcie, MD, Amgen
Pancreatic Cancer
12/23
04/26

Download Options